Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002â2006-Reference-Cited by-同舟云学术

Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002â2006

Published:2010-02 Issue:2 Volume:84 Page:117-127
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

ThÃ¶rn Ingrid,Forestier Erik,Thuresson Britt,Wasslavik Carina,Malec Maria,Li Aihong,LindstrÃ¶m-Eriksson Elenor,Botling Johan,Barbany Gisela,Jacobsson Stefan,Olofsson Tor,Porwit Anna,SundstrÃ¶m Christer,Rosenquist Richard

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2009.01374.x/fullpdf

Reference46 articles.

1. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood;van Dongen;Lancet,1998

2. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer â Childhood Leukemia Cooperative Group;Cave;N Engl J Med,1998

3. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia;Panzer-Grumayer;Blood,2000

4. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome;Nyvold;Blood,2002

5. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia;Dworzak;Blood,2002

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside;Experimental Hematology & Oncology;2022-09-03

2. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL;Annals of Hematology;2021-07-08

3. T-Cell Receptor Rearrangements Determined Using Fragment Analysis in Patients With T-Acute Lymphoblastic Leukemia;Annals of Laboratory Medicine;2019-03-31

4. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000;Cytometry Part B: Clinical Cytometry;2016-10-27

5. Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia;Revista Brasileira de Hematologia e Hemoterapia;2015-11